Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Jul 01, 2022 1:27am
202 Views
Post# 34795740

When Will They Ever Learn???

When Will They Ever Learn???Chronic Cough: 50 Patient Proof of Concept Study Completed in 10 Months in UK. https://www.businesswire.com/news/home/20220629005372/en/Axalbion-Announces-Positive-Findings-from-Phase-2-Clinical-Study-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist https://clinicaltrials.gov/ct2/show/NCT04866563 Jacky Smith (Principle Investigator) is on the Advisory Board of both Algernon Pharmaceuticals and Bellus Health, and likely other companies. She's a hired gun for Chronic Cough. It would appear that Algernon is the only company that struggles enormously to get to data results. It has everyone do with location and cheap tricks. Will management ever change their wicked ways? https://algernonpharmaceuticals.com/medical-and-scientific-advisory-board/ https://bellushealth.com/about-us/our-company/#chronic-cough-cab "We look forward to testing AX-8 in this proof-of-concept study, as there are currently no approved treatments for chronic cough. By activating TRPM8, our goal is to decrease the upper airway sensitivity in chronic cough patients, and reduce coughing and throat irritation, said principal investigator Jacky Smith, MD, professor of respiratory medicine at the University of Manchester, UK." https://WWW.BUSINESSWIRE.COM/news/home/20211020005271/en/Axalbion-Announces-First-Patients-Treated-in-Phase-2-Clinical-Trial-in-Chronic-Cough-with-AX-8-a-Novel-TRPM8-Agonist https://axalbion.com/
<< Previous
Bullboard Posts
Next >>